NAIINasdaqMedicinal Chemicals & Botanical ProductsFiscal year ends June 30
NATURAL ALTERNATIVES INTERNATIONAL INC
Financials through Q4 FY2026, quarter ended Jun 30, 2026Last filing: 10-K on Sep 28, 2026
$1.15+0.00 (0.00%)
Close on Oct 19, 2026
- Market cap
- $6.98M
- P/E (TTM)
- –
- Dividend yield
- –
Margins
Share of revenue, fiscal years 2012 to 2026
Gross margin
6.3%−10.7 pts over 5 years
Operating margin
-13.2%−20.8 pts over 5 years
Net margin
-14.5%−20.6 pts over 5 years
Growth rates
Compound annual growth to fiscal 2026
| Per year | 1 year | 3 years | 5 years | 10 years | Five-year pace |
|---|---|---|---|---|---|
| Revenue | +9.7% | -2.6% | -4.4% | +2.2% | |
| Gross profit | -3.1% | -20.9% | -21.6% | -9.8% |
Returns and balance sheet
10 fiscal years. Hover a measure to see how it is calculated.
| Measure | FY2017 | FY2021 | FY2026 | Trend |
|---|---|---|---|---|
| Return on equity | 12.6% | 14.2% | -35.0% | |
| Return on assets | 9.9% | 9.0% | -14.9% | |
| Current ratio | 5.03 | 3.64 | 1.73 | |
| Debt to equity | – | 0.00 | 0.20 | |
| Net debt to EBITDA | – | -1.78× | -0.20× | |
| Inventory turnover | 5.6× | 5.4× | 4.8× | |
| Capex to revenue | 4.4% | 2.9% | 2.6% | |
| Diluted shares | 7M | 6M | 6M |
Where the cash went
Fiscal 2022 to 2026, five years combined
Natural Alternatives International generated $35.23M from operations and spent $57.84M on capital expenditure, dividends and share buybacks. 87% of that went back into the business.
Generated
$35.23M
Used
$57.84M
Capital expenditure$50.34M87%Dividends$00%Share buybacks$7.49M13%
DuPont analysis
Return on equity split into margin, efficiency and leverage
Net margin-14.5%
×Asset turnover1.02×
×Equity multiplier2.35×
=Return on equity, FY2026-35.0%
| Fiscal year | Net margin | Asset turnover | Equity multiplier | Return on equity |
|---|---|---|---|---|
| FY2026 | -14.5% | 1.02× | 2.35× | -35.0% |
| FY2025 | -10.5% | 0.83× | 2.08× | -18.0% |
| FY2024 | -6.3% | 0.77× | 1.73× | -8.4% |
| FY2023 | 1.6% | 1.10× | 1.58× | 2.8% |
| FY2022 | 6.3% | 1.28× | 1.58× | 12.7% |
| FY2021 | 6.0% | 1.48× | 1.59× | 14.2% |
| FY2020 | -1.4% | 1.11× | 1.45× | -2.2% |
| FY2019 | 4.7% | 1.55× | 1.24× | 9.1% |
| FY2018 | 3.8% | 1.68× | 1.22× | 7.8% |
| FY2017 | 5.9% | 1.66× | 1.28× | 12.6% |
Piotroski F-Score
Nine tests of profitability, balance sheet and efficiency, fiscal 2026 against fiscal 2025
2of 9 tests passed in fiscal 2026. Scores of 7 to 9 are usually read as strong.
- ProfitableNet income above zero-$20.70M
- Cash generatingOperating cash flow above zero-$8.92M
- Return on assets improvedROA up on the prior year-8.4% → -13.6%
- Earnings backed by cashOperating cash flow above net income-$8.92M vs -$20.70M
- Less leverageLong-term debt to assets fell5.7% → 8.1%
- Better liquidityCurrent ratio rose2.06 → 1.73
- No dilutionShare count did not rise6M → 6M
- Gross margin improvedGross margin up on the prior year7.15% → 6.31%
- More efficientAsset turnover rose0.80 → 0.94